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Abstract
Background: Patient decision aids (DAs) are support tools designed to provide patients with relevant information
to help them make informed decisions about their healthcare. While DAs can be effective in improving patient
knowledge and decision quality, it is unknown what types of information and evidence are used to populate such
decision tools.
Methods: Systematic methods were used to identify and appraise the relevant literature and patient DAs published
between 2006 and 2015. Six databases (Academic Search Complete, AMED, CINAHL, Biomedical Reference Collection,
General Sciences and MEDLINE) and reference list searching were used. Articles evaluating the effectiveness of the DAs
were appraised using the Cochrane Risk of Bias tool. The content, quality and sources of evidence in the decision aids
were evaluated using the IPDASi-SF and a novel classification system. Findings were synthesised and a narrative
analysis was performed on the results.
Results: Thirteen studies representing ten DAs met the inclusion criteria. The IPDASI-SF score ranged from 9 to 16
indicating many of the studies met the majority of quality criteria. Sources of evidence were described but reports
were sometimes generic or missing important information. The majority of DAs incorporated high quality research
evidence including systematic reviews and meta-analyses. Patient and practice evidence was less commonly
employed, with only a third of included DAs using these to populate decision aid content. The quality of practice
and patient evidence ranged from high to low. Contextual factors were addressed across all DAs to varying degrees
and covered a range of factors.
Conclusions: This is an initial study examining the information and evidence used to populate DAs. While research
evidence and contextual factors are well represented in included DAs, consideration should be given to incorporating
high quality information representing all four pillars of evidence based practice when developing DAs. Further, patient
and expert practice evidence should be acquired rigorously and DAs should report the means by which such evidence
is obtained with citations clearly provided.
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Background
Patients are often required to make important decisions
about their treatment that will have a direct impact their
health [1, 2]. The provision of relevant information
about available treatment options and likely outcomes
empowers patients to make fully informed decisions and
determine their preferred options [3]. Shared decision
making is an approach where patients make decisions
together with their healthcare practitioner using the best
available evidence [4]. This approach promotes patient
engagement in the decision making process, enables
patients communicate their preferences and chose the
best treatment option having considered different alter-
natives [4–6]. A means of facilitating shared decision
making is through the use of decision support tools.
However, some decisions can be complex due to a lack
of evidence on treatment effectiveness and difficulties
finding the balance between the benefits and harms of
respective treatment options [3, 7]. Thus, a major chal-
lenge to shared decision making is ensuring decision
support materials are comprehensive and provide rele-
vant information that represents the totality of best
available evidence. Decision aids (DAs) are decision sup-
port tools ‘designed to help patients make decisions by
providing information on the options and outcomes rele-
vant to a person’s health status’ [5]. Effectively, a DA
brings together different types of knowledge about the
intervention being offered in order to assist the patient
to make fully informed decisions regarding that treat-
ment. DAs contribute to patients being actively in-
volved in their care and have been shown to lead to
higher decision quality, increased patient knowledge
and improved congruency between patient values and the
treatment chosen [3, 5, 6]. Further the inclusion of DAs in
consultations make them superior than those that depend
on the spoken word alone, which have the potential to
confuse patients [8]. Despite the effectiveness of DAs,
there are concerns about the type and level of evidence
being used to populate these decision tools and inconsist-
encies in evidence sources reported [9, 10].
A recent examination by Montori et al. [9] of 257
DAs found that even in the era of evidence based prac-
tice (EBP), approximately half provided citations for the
research evidence used to inform their content [9].
These findings compare well however to an earlier re-
view by Feldman-Stewart et al. [10] which identified
only one fifth of DAs as providing a list of citations
[10]. This suggests improvements in citation use over
the intervening period by DA developers and may re-
flect improved methods and guidelines for DA develop-
ment [11, 12]. Lack of transparent citing can lead to
difficulties in deciphering the quality, accuracy and reli-
ability of the information contained in DAs. Further,
even when evidence sources are reported, there are
indications of variations in the quality and quantity of
evidence used as shown by Montori et al. [9]. This
study reviewed a random sample of DAs (n = 20),
identifying that while half used high quality evidence
(systematic reviews, meta-analyses, numerous original
research articles, clinical practice guidelines), others
used less robust evidence (a narrative review, a singular
piece of original research, expert opinion) [9] demonstrat-
ing a lack of standardisation in the evidence contained
in DAs.
While research evidence is essential to guide decision
making, it can be argued that it does not reflect the
totality of evidence and is by itself not sufficient to facili-
tate patient-centred decision making [13]. EBP is a key
contemporary model informing clinical practice and in
its entirety can be proposed to comprise four pillars of
evidence: research evidence, practice evidence, patient
evidence and what can be termed contextual factors
[14, 15]. Contextual factors reflect on pragmatic con-
siderations such as cost, availability, policies and treat-
ment burden and are considered highly important in
influencing practice change [16]. Thus, it is purported
that DAs should include information representing all
four components to provide a more complete evidence
based account of each treatment. This however, is not
always the case. Feldman-Stewart [10] for example,
identified that only 40% of DAs contained patient expe-
riences [10] with many of these reflecting singular or a
small number of patients’ accounts rather than sum-
mated high quality patient evidence.
It is suggested that use of evidence from the four
components of EBP and the synthesis of such informa-
tion in DAs is required in order to effectively contrib-
ute to fully informed patients and evidence based
shared decision making. To the authors’ knowledge no
published study has evaluated DAs using a comprehen-
sive EBP framework. Thus, the aim of this review is to
examine the evidence being used in DAs so as to fully
understand what information patients receive to inform
their treatment decisions when using DAs. For this
purpose, the components of evidence based practice
(EBP) including research evidence, practice evidence,
patient evidence and contextual factors will be used to
guide the evaluation. In addition, the quality and source
of this information will also be established using a
novel grading classification framework.
Methods
This systematic review was conducted according to
the PRISMA 2009 checklist (Additional file 1) [17].
Treatment DAs evaluated using RCTs were reviewed
to examine if such decision tools reflect multiple
forms of evidence.
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Literature Search and article inclusion
The literature search was conducted in November 2015.
Search terms related to choice behaviour and decision
support interventions were used to identify articles (see
Table 1).
The following six databases were searched using the
above terms: Academic Search Complete, AMED,
CINAHL, Biomedical Reference Collection, General
Sciences and MEDLINE and reference list screening
was also conducted to source further eligible articles
(Fig. 1) including of large DA reviews such as Stacy et
al. [5]. Search years were restricted to 2006–2015 in re-
sponse to the publication of standards for decision aid
development and evaluation [12]. The primary inclu-
sion criteria were studies using RCTs to evaluate DAs
and the availability of those DAs for content examin-
ation at a later stage (Table 2). Titles and abstracts were
initially screened by one reviewer against predefined in-
clusion and exclusion criteria (Table 2) with articles
overtly inapplicable to the review topic excluded. The
remaining articles were independently (in isolation)
double screened and categorised by each reviewer using
a traffic light system of green (included), orange (poten-
tially eligible), or red (excluded). The reviewers then
met to agree final inclusions with disagreements being
resolved through discussion with a third reviewer.
Data extraction and analysis
Bias
The Cochrane Risk of Bias tool was used to evaluate the
articles related to the DAs across six domains: generation
of random allocation sequence, concealment of allocation
sequence, blinding, incomplete outcome data, selective
outcome reporting and other biases [18]. Articles were
assessed for bias by one reviewer with any ambiguity re-
solved through discussion with a second reviewer.
Quality of Decision aids
The short form of the International Patient Decision
Aid Standards Instrument (IPDASi-SF) was used to
assess the quality of the DAs [19, 20]. The IPDASi-SF
comprises 16 items across seven dimensions, including:
information, probabilities, values, development, disclos-
ure, decision support technologies evaluation, and
evidence. DAs were assessed by one reviewer with a
second reviewer evaluating a random sample of 30% of
DAs. Disagreements were resolved through discussion
between the two reviewers.
Evidence used in DAs
As no tool existed to complete this task, a novel classi-
fication tool (Additional file 2) was developed by the
authors to analyse the various types of evidence ob-
tained through data extraction. The purpose of this tool
was to determine the extent to which research, practice,
patient and contextual evidence were incorporated
within DA content, the methodological rigour used to
obtain this evidence and the clarity of evidence sources
within the DA. Supporting documentation (articles)
was used to clarify/establish information where neces-
sary. The extraction tool consisted of a hierarchy of
classification criteria for each form of evidence. The
criteria for research evidence was categorised according
to an eight-point rubric based on evidence level and
transparency ranging from A1 (systematic reviews of
randomised clinical trials (RCTs), meta-analyses or
multiple RCTs with sources available in DA or associ-
ated documents) to D2 (use of research evidence not
evident). The criteria were based on the levels of evi-
dence from the European Society of Cardiology guide-
lines [21] and aligned to the hierarchy of evidence
Table 1 Search Terms
1. choice behav*/
2. decision making/
3. shared decision making/
4. information seeking behav*/
5. help seeking behav*
6. or/1–5
7. ((decision) adj (support* or aid or tool or instrument or technolog*
or technique* or system* or program* or algorithm* or process* or
method* or intervention* or material* or board* or guide* or
counselling*)).tw.
8. ((decision support) adj (system* clinical or technolog*)).tw.
9. education technology/
10. communication package/
11. decision tree*/
12 ((risk) adj (communication or assessment)).tw.
13. ((risk information) adj (tool or method)).tw.
14 ((interactive) adj (health communication or booklet or graphic or
tool)).tw.
15. ((informed) adj (choice or decision)).tw.
16. or/7–15
17. clinical trial/
18. ((randomized or randomised) adj (controlled trial)).tw.
19. controlled clinical trial/
20. randomized/
21. randomised/
22. placebo/
23. random/
24. trial/
25. double blind method/
26. or/17–25
27. 6 and 16 and 26
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outlined in the OCEBM Levels of Evidence tables [22].
Practice and patient evidence consisted of a seven-
point rubric ranging from A1 (expert or clinical con-
sensus of ≥15 participants obtained directly or through
published evidence with evidence sources available in
DA or associated documents) to D (no evidence in-
cluded). Factors considered in classification related to
the number of participants, the strength of method-
ology employed in obtaining the information and the
clarity of evidence sources within the DA. Direction for
a representative sample size was guided by recommen-
dations for powering Delphi consensus, which sug-
gests a minimum of 15 respondents [23]. Thus, the
grading system awarded a higher score for studies in-
cluding 15 or more participants for practice or patient
evidence. Criteria for contextual factors were simpli-
fied to a three-point scale based on quantity ranging
from A (includes multiple contextual factors e.g. time,
cost, resources for each treatment option) to C (does
not include any contextual factors). The tool was
tested by three reviewers and went through an itera-
tive process (five iterations) until the authors were sat-
isfied that the criteria accurately represented the types
of evidence and specific factors to be addressed. Data
extraction and grading was completed by three re-
viewers independent from each other. One reviewer
conducted extraction and grading for all DAs while
two other reviewers evaluated a 50% sample each. Dis-
agreements were discussed and resolved between the
reviewing team.
Results
Results of search
The literature search yielded a total of 1732 unique cita-
tions with an additional 17 identified through reference
list screening. Thirteen studies representing ten treatment
DAs were included in the review [24–36]. Figure 1 depicts
the flow of studies through the search process.
Study characteristics
Eleven studies were conducted in North America [24–29,
31–34, 36], one in the UK [30] and one in Canada and
Australia [35] thus predominately representing Anglo-
Saxon countries. The DAs covered a range of health con-
ditions including: cardiovascular disease [25, 29, 36], type
2 diabetes [25, 30, 33], osteoporosis [27, 31], breast cancer
[26], cystic fibrosis [35], depression [28], post-traumatic
stress disorder [32], uterine fibroids [34] and weight loss
surgery in obesity [24]. DA interventions were delivered in
a variety of formats including single page documents [25,
27, 29, 31, 36], booklets [30, 32, 35], cards [25, 28, 33],
booklet and video [24, 34] and computer-based DAs [26].
Patients participating in the trials were from a range of
settings including: primary care [25, 27–29, 31, 33], spe-
cialist clinics [26, 32, 34, 36], general practice [30], health
plan systems [24] and outpatient centres [35] (Table 3).
Cochrane Risk of Bias
A summary of the risk of bias is shown in Table 4.
Sequence generation was deemed to be of low risk of
bias in 8/13 (61.5%) studies [24, 26, 27, 31–33, 35, 36].
Fig. 1 Prisma Diagram
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Selective reporting was deemed to be low risk in 8/13
studies as trial registration or protocols were available
publicly [25, 27–31, 33, 35, 36] and unclear in the
remaining. Incomplete outcome data was adequately de-
scribed in 8/13 studies [27–31, 34–36]. Nine (69.2%)
studies were deemed to be free of other sources of bias
[24, 26, 27, 31–36], it being not possible to judge the
remaining studies. Allocation concealment was rated as
unclear in 9/13 studies [24–29, 32, 34, 36]. Blinding of
participants and study personnel was unclear 11/13
(84.6%) studies [24–27, 29–35]. Four individual studies
reported on bias as follows: Branda [25] noted the possi-
bility for selection bias due to incomplete recruitment of
patients and clinicians within each cluster [25]; LeBlanc
[28] reported a 20% loss to follow-up at primary end-
point which may have increased risk of bias in favour of
intervention [28]; Mann [29] stated that clustering ef-
fects were not adjusted but did not report on change in
data as a result of this [29], and; Mathers [30] noted a
potential recruitment bias as more participants were al-
located to the intervention than the control group [30].
Decision Aid Quality (IPDASi-SF)
The ten unique DAs were assessed using the IPDASi-SF.
The rationale for scores is explained fully in previous re-
search [19]. Overall, the DA scores ranged from 9 to 16
(mean 13 ± 2.11) thus ranging from moderate to excellent
quality (Table 5). All DAs for example, met the criteria re-
lated to information with all aids scoring maximum points
in this section. DAs also scored highly on items related
to development including the assessment of patient
needs (9/10) and completing testing with patients (7/10).
DAs reported a positive effect on user knowledge (9/10)
and decision quality (7/10). The reporting of event rates
(the communication of the likelihood of an outcome
occurring) was completed least often (5/10).
Evidence levels and sources in decision aids (novel
framework)
Table 6 outlines the types of evidence retrieved from the
included DAs.
Research evidence
Research evidence was well represented in most DAs
evaluated (Table 6). The majority (7/10) incorporated a
range of research evidence including articles of high
methodological rigour such as systematic reviews, meta-
analyses or randomised controlled trials. One DA was
categorised as an A2 as it used a combination of national
clinical guidelines and a cohort study to populate con-
tent [30]. In some cases, it was unclear as to the type
and rigour of research evidence used to inform DA con-
tent and this was reflected in categorisation. Mott et al.
[32] for example, referred to research findings but did
not provide citations to studies used [32]. Vandemheen
(2010) reported that the DA content was based on a lit-
erature review, patient interviews and data from a na-
tional registry [35] but did not delineate the sources of
all DA information.
Practice Evidence
Use of practice evidence to populate DA content was
less evident being incorporated into only 3/10 DAs
(Table 6). Two DAs, produced by the same organisa-
tion, were categorised as B1 on the grading rubric as
they directly incorporated clinicians’ opinions through
interview methods [24, 34]. Despite this, both DAs
recruited less than 15 clinicians/experts and therefore
did not receive the maximum score. One DA [27, 31]
was graded as C2 despite incorporating practice evi-
dence as it utilised an unknown number of members of
the research team to retrieve this evidence which was
also not presented explicitly within the aid and used
mainly to supplement low level research evidence about
the specific topic [37].
Patient evidence
A third (3/10) of DAs integrated patient evidence as a
source of information (Table 6). Two DAs, produced by
the same organisation scored A1 in this category inter-
viewing 30 people considered to represent the target audi-
ence [24, 34]. The methodology, number of participants
and explicit presentation of patient evidence justified the
Table 2 Inclusion and exclusion criteria
Inclusion Criteria
• Studies investigating treatment choices for an established health
condition
• Studies (randomised controlled trial design) comparing DAs to usual
care, no intervention, alternative interventions
• Studies for which the decision aids being investigated were
available to the research team for subsequent content examination
• Studies for which there was availability of associated documentation
detailing development process of the decision aid
• Articles published in English language
Exclusion criteria
• Studies including hypothetical choices
• Decisions aids regarding:
○ clinical trial entry
○ screening/assessment
○ advance health care directives (e.g. resuscitation status)
○ educational programmes not directed toward decision making
○ promoting adherence only
○ eliciting informed consent only
• Decisions made by a surrogate or guardian for a patient
• Decision aids developed before 2006
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highest grade for this category. The other DA graded as
B2 as it incorporated hypothetical patient stories played
by actors but did not report on how the script was devel-
oped [26].
Contextual factors/evidence
Contextual factors were generally addressed to some
degree by all DAs (Table 6). The majority (9/10) typic-
ally presented 1–2 contextual factors per treatment
option. One DA presented more than two [35]. Issues
addressed by DAs aids included: daily routine (6/10)
including dose and particulars such as how to take
medication, cost (5/10), length of hospital stay, if any
(3/10), time to execute treatment including consult-
ation length and/or number of weekly sessions involved
(2/10), and other practical issues e.g. self-monitoring
(1/10), waiting time for procedure (1/10) and extra test-
ing or doctor visits (1/10) as a result of the treatment.
Discussion
The DAs examined in this study reflect a highly speci-
fied rather than generic group i.e. they were treatment
DAs (they did not for example represent those used for
assessment), representing Anglo-Saxon countries, eval-
uated using RCTs which had supporting documentation
available in the form of published papers and technical
documents. Thus, the review focused on a small num-
ber of DAs which met these criteria and the study find-
ings should be interpreted with this in mind.
Quality and transparency of DAs
The purpose of the IPDASi-SF is to present an overall
impression of quality based on whether DAs contain
suggested components and complete a rigorous devel-
opment and evaluation process. According to the
IPDASi-SF, the DAs reviewed in this study were of gen-
erally good quality, with many aids scoring maximally
on rigour of development. This may be partially ex-
plained given that the evaluation of research content
according to this tool refers predominately to the
provision of research citations and not for example, the
appropriate use of research to inform DA content.
Thus, the IPDASi-SF differs from the novel classifica-
tion tool developed for this review which assessed all
evidence types and determined the quality of evidence
according to evidence type and transparency. This
demonstrated that a high score on the IPDASi-SF did
not necessarily correlate with a high classification grade
on using the novel classification tool used in this re-
view. This suggests that while the quality of DAs as
assessed using the IPDASi-SF may be sound, the variety
of evidence used and the rigour of evidence sources
other than research evidence are not guaranteed.
The majority of DAs provided citations for research
evidence used to populate content either in the DA it-
self or in the supporting documentation representing
variety in reporting methods. Two DAs developed by
the same organisation, provided references within the
DA [24, 34]. For one DA, the author was contacted to
retrieve this information as there was no source refer-
ences provided [32]. The remaining six DAs reported
the sources of evidence either in papers detailing the
development of the DA or in unpublished technical or
background documents. In some cases, it was not
clear whether citations were provided for all sources
of information used to inform content. For example,
in one DA citations were only provided for one of
three treatment options included [30] the resultant
score reflecting this. Thus, it was frequently challen-
ging to assign DAs a score due to the lack of transpar-
ency in reporting evidence sources. Such findings are
in line with similar results from a review of health in-
formation for patients (which includes DAs), which
identified a high proportion of health information
failed to disclose their evidence sources [9, 10]. It can
be considered more surprising in this case given that
the DAs included in this study had supporting docu-
mentation available. For patient, practice and context-
ual evidence, while sources were often available in
associated documentation, reporting of this informa-
tion was often generic and sometimes confusing.
Given the importance of making correct and appropri-
ate treatment decisions, evidence sourcing in DAs
should without doubt be made explicit and transpar-
ent in order to allow the various stakeholders interpret
information and make judgements about its usefulness
and reliability, thus enabling patients to make more
informed decisions.
Content of Decision Aids
Research evidence and contextual factors
This novel review found that the information used to
inform the content of the ten DAs examined is primar-
ily founded on research evidence and contextual fac-
tors. Research evidence was well represented across the
DAs evaluated, the majority using high quality research
evidence categorised according to the A descriptor.
This compares to the findings of a systematic review by
Montori et al. [9], which found that half of the DAs ex-
amined used high quality evidence [9]. Furthermore, for
the DAs examined the research evidence was explicit as
citations for research evidence were provided in almost
all aids. This finding compares favourably to previous
research, which identified between a fifth (21%) to half
(50%) of DAs provided citations for research evidence
[9, 10]. The difference in findings may be explained by
a number of factors, specifically the particular nature
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(treatment) of the DAs included in each study, the rela-
tive recency of those in the current study which reflect
on the application of the 2006 IPDAS standards [12]
and the bias that may result from including only DAs
which had supporting documentation. While this was
necessary to examine DA content in depth, it also lim-
ited inclusion and therefore may not represent all avail-
able DAs, implying that Montori et al’s [9] and
Feldman-Stewart et al’s [10] findings may be more rep-
resentative of the general pool of DAs. Topics regard-
ing the medical condition, treatment options, expected
outcomes and side effects were generally informed by
research evidence reflecting standards advocated by
International Standards for Patient Decision Aids Col-
laboration [12]. DAs which scored lower in this domain
did so either because of lack of availability of high qual-
ity evidence or by not providing sufficient information
to enable an evaluation to be made of the quality and
sources of evidence. One DA reported using treatment
manuals and a national website dedicated to the condi-
tion for treatment information [32] raising issues of in-
formation bias and comprehensiveness. In order to
facilitate fully informed decision making by patients,
up-to-date and complete scientific evidence should be
used in DA content [10] which can be achieved via a
systematic process of reviewing the literature and expli-
citly reporting scientific uncertainty where applicable
[1]. Notably, most of the randomised controlled trials
evaluating the effectiveness of the DAs were mainly of
unclear bias, demonstrating that even when the appro-
priate study design is implemented it does not guaran-
tee the quality of evidence within the DA itself.
As with research evidence, contextual evidence was
reported in all aids with a wide range of factors being
addressed and each DA containing at least one such
factor. The inclusion of contextual information, par-
ticularly those representing treatment burden such as
out-of-pocket costs and treatment intensity, can be
seen as highly patient-centric given that such factors
have the potential to dominate patient decision making
[38]. DAs which include such content are likely to be
more patient relevant and user friendly. Furthermore,
complementing research evidence with matters related to
the specific sociocultural context of the patient may serve
to improve patient engagement with information [39].
Practice evidence and patient evidence
Practice and patient evidence were conversely not well
represented in DA content with only a small subset of
DAs incorporating this type of evidence. Further, the
quality of such evidence varied and the sourcing of this
information was not always transparent suggesting less
rigorous rules for obtaining and using such evidence.
Practice evidence was least commonly used to populate
DAs with the majority (70%) not incorporating any
clinical or expert evidence. This absence exists despite
findings which demonstrate that patients value the
opinion of health professionals when making decisions
[40] and often regard clinical opinion as more import-
ant than information on intervention risks and benefits
[41]. This relative lack of inclusion of practice evidence
in DAs may be due to a number of factors including
the perception of clinical expertise as a less reliable or
significant form of evidence [22, 42]. It may also eman-
ate from a perception that asking clinicians to comment
on the aid during the design phase (rather than contrib-
ute collectively to the content) constitutes practice evi-
dence. Additionally, the patient-clinician conversation
Table 4 Cochrane Risk of Bias results
Criteria Sequence
generation
Allocation concealment Blinding (participants, personnel
and outcome assessors)
Incomplete
outcome data
Selective outcome
reporting
Other sources
of bias
Arterburn 2011 [24] + ? ? ? ? +
Branda 2013 [25] ? ? ? ? + ?
Jibaja-Weiss 2011 [26] + ? ? ? ? +
LeBlanc 2015 [27] + ? ? + + +
LeBlanc 2015 [28] ? ? - + + ?
Mann 2010 [29] ? ? ? + ? ?
Mathers 2012 [30] ? + ? + + ?
Montori 2011 [31] + + ? + + +
Mott 2014 [32] + ? ? ? ? +
Mullan 2009 [33] + + ? ? + +
Solberg 2010 [34] ? ? ? + ? +
Vandemheen 2009 [35] + + ? + + +
Weymiller 2007 [36] + ? + + + +
+ Low risk; ? Unclear risk; - High risk
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itself when using DAs may be interpreted as utilising
practice evidence suggesting that, unlike with research
evidence, a singular clinical opinion may be considered
sufficient to represent this form of evidence. Of the
DAs in this study that incorporated practice evidence,
two used clinicians to present factual information, such
as describing treatment features, as well as report their
clinical opinions [24, 34]. There was a lack of transpar-
ency with regards to how such experts were selected.
Another DA supplemented weak research evidence
about medication side-effects with clinical knowledge
from the design team. This was retrieved through dis-
cussion and it is not known how many clinicians were
consulted in the process [37]. Thus, in both cases issues
with methodology and rigour in attaining practice evi-
dence were present. The differences observed in re-
trieval and use between practice and research evidence
suggests different value systems for different types of
evidence. Practice evidence when used appears not to
be rigorously obtained through formal methodologies,
rather being frequently obtained through members
(often few in number and unspecified) of the DA design
team. Moreover, it appears primarily used as a supple-
mentary source of information (especially when re-
search evidence is lacking) rather than in its own right.
As for research evidence, it is no less important to
understand how and where from practice evidence is
retrieved in order to ensure unbiased and systematically
obtained information is delivered to patients [1].
The use of patient evidence in DAs is a contentious
area with lack of consensus regarding its optimal use
[39, 43]. This is reflected in the limited use of patient
evidence in the DAs examined with the majority, (70%)
not incorporating patient experiences and opinions. This
is analogous to findings regarding practice evidence sug-
gesting a corresponding low valuing for this type of in-
formation. It is in contradiction to patient evidence
having been shown to facilitate patient understanding,
coping with illness and adjustment to treatment [44–46],
it being a useful means of providing insight into a par-
ticular experience about a condition. Research suggests
that patients experiencing a range of health conditions
have expressed positive responses to inclusion of patient
evidence in health information and would like it to be
integrated in health education [44]. There are clear sug-
gestions of the relative valuing of such information by
patients: they regard narrative information to be as cred-
ible as research evidence, and; patient narratives are sug-
gested to be more persuasive than research evidence
with patients often basing their treatment decision on
the experiences of others above factual representations
[43, 47, 48]. Thus, decision aid developers may pur-
posely limit the focus on patient evidence in DA content
both because of lowly valuing of such information and
due to concerns around its optimal use for promoting
unbiased, informed decisions [43]. These concerns may
be balanced by involving patients in DA development
from the offset for example, by providing input on the
range of outcomes that patients consider critical in deci-
sion making (in addition to researcher-driven outcomes)
and incorporating user panels comprising patients and
caregivers (in addition to clinicians, experts and re-
searchers) in an iterative design process focused on
representing and balancing all forms of evidence [13].
Inclusion of patient evidence in DAs would address the
real life experiences of decision aid users [49], thus
Table 6 Evidence used in decision aids
Publications Decision aid Pillar of evidence
Research
evidence
Practice
evidence
Patient
evidence
Contextual
evidence
Arterburn 2011 [24] Weight Loss Surgery: Is it right for you? A1 B1 A1 B
Jibaja-Weiss 2011 [26] A Patchwork of Life: One Woman’s Story A1 D B2 B
LeBlanc 2015 [27], Montori 2011 [31] Osteoporosis Choice A1 C2 D B
LeBlanc 2015 [28] Depression Medication Choice A1 D D B
Mathers 2012 [30] Starting Insulin. Your Choice. A2 D D B
Mott 2014 [32] Getting help for PTSD: A guide to finding
the right treatment for you
D1 D D B
Mullan 2009 [33], Branda 2013 [25] Diabetes Medication Choice A1 D D B
Solberg 2010 [34] Treatment choices for uterine fibroids A1 B1 A1 B
Vandemheen 2009 [35] When your lung function is getting worse…
Should you be referred for a lung transplant?
A decision aid for adults with cystic fibrosis
D1 D D A
Weymiller 2007 [36], Mann 2010 [29],
Branda 2013 [25]
Statin Choice A1 D D B
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empowering patients to make decisions based on a range
of information that considers their individual context,
goals, values and preferences.
The reduced practice and patient content in DAs may
further reflect under researching (and thus lack of
availability) of these forms of evidence. Thus, there is a
requirement for both forms of evidence to be acquired
using established research methods. Such methodologic-
ally rigorous research would help improve the reliability
and validity of such evidence in addition to strengthen-
ing the relevant content used in DAs. It would also be
useful when evaluating DAs which have been developed
with the totality of evidence in mind, that studies be
undertaken to examine how patients’ decisions are in-
fluenced by such individual forms of evidence. Further,
as Violette et al. [50] point out, the content of DAs
needs to remain current [50] to reflect additional and
evolving evidence and policy developments.
These recommendations reflect a global move toward
patient inclusion in their health care in a variety of ways
specifically regarding fully informed shared decision mak-
ing. As for other decision support tools, the development
of DAs is a positive step in this regard and their import-
ance is highlighted in policy and legal developments such
as The Patient Protection and Affordable Care Act (2010)
in the United States of which Section 3506 calls for the
creation of a certification and quality process for patient
decision aids and for best practices which include the
sharing of developed tools [51]. Such quality processes
should include the inclusion of multiple forms of evi-
dence, rigorously acquired evidence irrespective of type
and explicit sourcing of information used in DA content.
To further progress this constructive movement, it is im-
portant moving forward that information representative-
ness, transparency and selectivity in DAs are targeted in
order to best and fairly meet patient needs.
Limitations
As noted, DAs examined in this study reflect a targeted
rather than generic group and inclusion for review was
limited to those which were evaluated using RCTs which
were published in the literature. Thus, the nature of the
study meant a lot of DAs were not included in this review
and the finding cannot be readily generalised to all DAs.
Due to the lack of available tools and need to assess
the rigour of patient, practice and contextual evidence,
a novel grading system was developed. While unvalid-
ated, this tool went through five iterations before applica-
tion and was both comprehensive and reflective of the
issues being addressed. Further, assessment was completed
blindly by two independent reviewers and results were
cross-checked by a third reviewer in order to ensure rigor
and robustness of methodology employed and results
obtained.
This study primarily focused on representativeness of
information content. Thus information accuracy such as
appropriate use of citations was not included in the ana-
lysis at this stage.
Conclusion
The results of the current review demonstrate that the
content of treatment DAs is informed mainly by the
results of high quality research evidence and some
contextual factors with patient and practice evidence
being rarely incorporated. The transparency of report-
ing evidence sources can also be problematic especially
where multiple documents exist regarding the develop-
ment of the aid. Where patient or practice evidence is
used, there are seldom rigorous, research-based methods
used for obtaining this information. The same rigour used
to retrieve and select research evidence for DAs is re-
quired for other forms of evidence to reduce information
bias, improve the quality of DAs and enhance informed
decision making.
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